Exercise as an adjunctive treatment for cannabis use disorder

References

• Center for Behavior Health Statistics and Quality. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). Rockville, MD: Substance Abuse and Mental Health Services Administration. 2015.
   Google Scholar
• Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, et al. Prevalence of marijuana use disorders in the united states between 2001–2002 and 2012–2013. JAMA Psychiatry 2015;72:1.
   Web of Science ®Google Scholar
• Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci 2015;350:59–62.
   PubMed Web of Science ®Google Scholar
• Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract 2007;4:4–16.
   PubMedGoogle Scholar
• National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services. Treatment Approaches for Drug Addiction. Available from: http://www.drugabuse.gov/publications/drugfacts/treatment-approaches-drug-addiction [ last accessed January 2016].
   Google Scholar
• Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat 2008;35:362–368.
   PubMed Web of Science ®Google Scholar
• Gorelick DA, Levin KH, Copersino ML, Heishman SJ, Liu F, Boggs DL, Kelly DL. Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend 2012;123:141–147.
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol 2008;59:29–53.
   PubMed Web of Science ®Google Scholar
• Brown SA, Vik PW, Patterson TL, Grant I, Schuckit MA. Stress, vulnerability and adult alcohol relapse. J Stud Alcohol 1995;56:538–545.
   PubMed Web of Science ®Google Scholar
• Hendershot CS, Witkiewitz K, George WH, Marlatt GA. Relapse prevention for addictive behaviors. Subst Abuse Treat Prev Policy 2011;6:17.
   PubMed Web of Science ®Google Scholar
• Smit ES, Hoving C, Schelleman-Offermans K, West R, de Vries H. Predictors of successful and unsuccessful quit attempts among smokers motivated to quit. Addict Behav 2014;39:1318–1324.
   PubMed Web of Science ®Google Scholar
• Linke SE, Ussher M. Exercise-based treatments for substance use disorders: evidence, theory, and practicality. Am J Drug Alcohol Abuse 2015;41:7–15.
   PubMed Web of Science ®Google Scholar
• Dunn AL, Jewell JS. The effect of exercise on mental health. Curr Sports Med Rep 2010;9:202–207.
   PubMed Web of Science ®Google Scholar
• Kredlow MA, Capozzoli MC, Hearon BA, Calkins AW, Otto MW. The effects of physical activity on sleep: a meta-analytic review. J Behav Med 2015;38:427–449.
   PubMed Web of Science ®Google Scholar
• Buchowski MS, Meade NN, Charboneau E, Park S, Dietrich MS, Cowan RL, Martin PR. Aerobic exercise training reduces cannabis craving and use in non-treatment seeking cannabis-dependent adults. PLoS One 2011;6:e17465.
   PubMed Web of Science ®Google Scholar
• Tsatoulis A, Fountoulakis S. The protective role of exercise on stress system dysregulation and comorbidities. Ann N.Y.Acad Sci 2006;1083:196.
   PubMed Web of Science ®Google Scholar
• McAuley E, Blissmer B. Self-efficacy determinants and consequences of physical activity. Exerc Sport Sci Rev 2000;28:85–88.
   PubMedGoogle Scholar
• Kirkcaldy BD, Shephard RJ, Siefen RG. The relationship between physical activity and self-image and problem behaviour among adolescents. Soc Psychiatry Psychiatr Epidemiol 2002;37:544–550.
   PubMed Web of Science ®Google Scholar
• Wang D, Wang Y, Wang Y, Li R, Zhou C. Impact of physical exercise on substance use disorders: a meta-analysis. PLoS One 2014;9:e110728.
   PubMed Web of Science ®Google Scholar
• Zschucke E, Heinz A, Ströhle A. Exercise and physical activity in the therapy of substance use disorders. Sci World J 2012;2012:901741.
   Web of Science ®Google Scholar
• Lynch WJ, Peterson AB, Sanchez V, Abel J, Smith MA. Exercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis. Neurosci Biobehav Rev 2013;37:1622–1644.
   PubMed Web of Science ®Google Scholar
• Ussher MH, Taylor A, Faulkner G. Exercise interventions for smoking cessation. Cochrane Database Syst Rev 2012;1:CD002295.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS). 1998–2008. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-50, HHS Publication No. (SMA) 09-4471, Rockville, MD, 2010.
   Google Scholar
• Flemmen G, Unhjem R, Wang E. High-intensity interval training in patients with substance use disorder. Biomed Res Int 2014;2014:616935.
   PubMed Web of Science ®Google Scholar
• Roessler KK. Exercise treatment for drug abuse-a Danish pilot study. Scand J Public Health 2010;38:664–669.
   PubMed Web of Science ®Google Scholar
• Brown RA, Abrantes AM, Read JP, Marcus BH, Jakicic J, Strong DR, Oakley JR, et al. A pilot study of aerobic exercise as an adjunctive treatment for drug dependence. Ment Health Phys Act 2010;3:27–34.
   PubMedGoogle Scholar
• Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system. Neuroreport 2003;14:2209–2211.
   PubMed Web of Science ®Google Scholar
• Raichlen DA, Foster AD, Gerdeman GL, Seillier A, Giuffrida A. Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the “runner”s high’. J Exp Biol 2012;215:1331–1336.
   PubMed Web of Science ®Google Scholar
• Raichlen DA, Foster AD, Seillier A, Giuffrida A, Gerdeman GL. Exercise-induced endocannabinoid signaling is modulated by intensity. Eur J Appl Physiol 2013;113:869–875.
   PubMed Web of Science ®Google Scholar
• Heyman E, Gamelin F-X, Goekint M, Piscitelli F, Roelands B, Leclair E, Di Marzo V, Meeusen R. Intense exercise increases circulating endocannabinoid and BDNF levels in humans–possible implications for reward and depression. Psychoneuroendocrinology 2012;37:844–851.
   PubMed Web of Science ®Google Scholar
• Feuerecker M, Hauer D, Toth R, Demetz F, Hölzl J, Thiel M, Kaufmann I, et al. Effects of exercise stress on the endocannabinoid system in humans under field conditions. Eur J Appl Physiol 2012;112:2777–2781.
   PubMed Web of Science ®Google Scholar
• Koltyn KF, Brellenthin AG, Cook DB, Sehgal N, Hillard C. Mechanisms of exercise-induced hypoalgesia. J Pain 2014;15:1294–1304.
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561–564.
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946–1949.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kodaka T, Kondo S, Tonegawa T, Nakane S, Kishimoto S, Yamashita A, Waku K. 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun 1996;229:58–64.
   PubMed Web of Science ®Google Scholar
• Hohmann AG, Herkenham M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 2000;37:71–80.
   PubMed Web of Science ®Google Scholar
• Lupica CR, Riegel AC. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 2005;48:1105–1116.
   PubMed Web of Science ®Google Scholar
• Howlett AC, Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 2000;108:53–70.
   PubMed Web of Science ®Google Scholar
• Fuss J, Gass P. Endocannabinoids and voluntary activity in mice: runner’s high and long-term consequences in emotional behaviors. Exp Neurol 2010;224:103–105.
   PubMed Web of Science ®Google Scholar
• Olsen CM. Natural rewards, neuroplasticity, and non-drug addictions. Neuropharmacology 2011;61:1109–1122.
   PubMed Web of Science ®Google Scholar
• Brené S, Bjørnebekk A, Aberg E, Mathé AA, Olson L, Werme M. Running is rewarding and antidepressive. Physiol Behav 2007;92:136–140.
   PubMed Web of Science ®Google Scholar
• Dubreucq S, Koehl M, Abrous DN, Marsicano G, Chaouloff F. CB1 receptor deficiency decreases wheel-running activity: consequences on emotional behaviours and hippocampal neurogenesis. Exp Neurol 2010;224:106–113.
   PubMed Web of Science ®Google Scholar
• Rasmussen EB, Hillman C. Naloxone and rimonabant reduce the reinforcing properties of exercise in rats. Exp Clin Psychopharmacol 2011;19:389–400.
   PubMed Web of Science ®Google Scholar
• De Chiara V, Errico F, Musella A, Rossi S, Mataluni G, Sacchetti L, Siracusano A, et al. Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum. Neuropsychopharmacology 2010;35:374–387.
   PubMed Web of Science ®Google Scholar
• Fuss J, Steinle J, Bindila L, Auer MK, Kirchherr H, Lutz B, et al. A runner’s high depends on cannabinoid receptors in mice. Proc Natl Acad Sci USA 2015;112:13105–13108.
   PubMed Web of Science ®Google Scholar
• You T, Disanzo BL, Wang X, Yang R, Gong D. Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise. Lipids Health Dis 2011;10:194.
   PubMed Web of Science ®Google Scholar
• Fernández-Aranda F, Sauchelli S, Pastor A, Gonzalez ML, de la Torre R, Granero R, Jiménez-Murcia S, et al. Moderate-vigorous physical activity across body mass index in females: moderating effect of endocannabinoids and temperament. PLoS One, 2014;9:e104534.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Côté M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli F, et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009;52:213–217.
   PubMed Web of Science ®Google Scholar
• Gasperi V, Ceci R, Tantimonaco M, Talamonti E, Battista N, Parisi A, Florio R, et al. The fatty acid amide hydrolase in lymphocytes from sedentary and active subjects. Med Sci Sports Exerc 2014;46:24–32.
   PubMed Web of Science ®Google Scholar
• Antunes HKM, Leite GSF, Lee KS, Barreto AT, Santos RVT Dos, Souza H de S, Tufik S, de Mello MT. Exercise deprivation increases negative mood in exercise-addicted subjects and modifies their biochemical markers. Physiol Behav 2016;156:182–190.
   PubMed Web of Science ®Google Scholar
• Mangieri RA, Hong K-IA, Piomelli D, Sinha R. An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology 2009;205:63–72.
   PubMed Web of Science ®Google Scholar
• Morgan CJA, Page E, Schaefer C, Chatten K, Manocha A, Gulati S, Curran HV, Brandner B, Leweke FM. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br J Psychiatry 2013;202:381–2.
   PubMed Web of Science ®Google Scholar
• Gorzalka BB, Hill MN, Hillard CJ. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 2008;32:1152–1160.
   PubMed Web of Science ®Google Scholar
• Hill MN, Carrier EJ, Ho W-SV, Shi L, Patel S, Gorzalka BB, Hillard CJ. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus. Hippocampus 2008;18:221–226.
   PubMed Web of Science ®Google Scholar
• Patel S, Roelke CT, Rademacher DJ, Hillard CJ. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 2005;21:1057–1069.
   PubMed Web of Science ®Google Scholar
• Rademacher DJ, Meier SE, Shi L, Ho W-SV, Jarrahian A, Hillard CJ. Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 2008;54:108–116.
   PubMed Web of Science ®Google Scholar
• Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009;34:1257–1262.
   PubMed Web of Science ®Google Scholar
• Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, Hillard CJ,et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci USA 2010;107:9406–9411.
   PubMed Web of Science ®Google Scholar
• Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, Gorzalka BB. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005;30:508–515.
   PubMed Web of Science ®Google Scholar
• Hill MN, Patel S. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol Mood Anxiety Disord 2013;3:19.
   PubMedGoogle Scholar
• McDermott MS, Marteau TM, Hollands GJ, Hankins M, Aveyard P. Change in anxiety following successful and unsuccessful attempts at smoking cessation: cohort study. Br J Psychiatry 2013;202:62–67.
   PubMed Web of Science ®Google Scholar
• Sinha R. New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep 2011;13:398–405.
   PubMed Web of Science ®Google Scholar
• González S, Cebeira M, Fernández-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 2005;81:300–318.
   PubMed Web of Science ®Google Scholar
• Muhl D, Kathmann M, Hoyer C, Kranaster L, Hellmich M, Gerth CW, Faulhaber J, et al. Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. Naunyn Schmiedebergs Arch Pharmacol 2014;387:691–695.
   PubMed Web of Science ®Google Scholar
• Goodwin RS, Baumann MH, Gorelick DA, Schwilke E, Schwope DM, Darwin WD, Kelly DL, et al. CB1 – cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men. Am J Drug Alcohol Abuse 2012;38:114–119.
   PubMed Web of Science ®Google Scholar
• Villares J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 2007;145:323–334.
   PubMed Web of Science ®Google Scholar
• Ceccarini J, Kuepper R, Kemels D, van Os J, Henquet C, Van Laere K. [(18) F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict Biol 2015;20:357–367.
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Goodwin RS, Li C-T, Terry GE, Zoghbi SS, Morse C, Pike VW, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 2012;17:642–649.
   PubMed Web of Science ®Google Scholar
• Ceccarini J, Hompes T, Verhaeghen A, Casteels C, Peuskens H, Bormans G, Claes S, Van Laere K. Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J Neurosci 2014;34:2822–2831.
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, Li C-T, et al. Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry 2013;18:916–921.
   PubMed Web of Science ®Google Scholar
• Hedges DW, Woon FL. Alcohol use and hippocampal volume deficits in adults with posttraumatic stress disorder: A meta-analysis. Biol Psychol 2010;84:163–168.
   PubMed Web of Science ®Google Scholar
• Smith ME. Bilateral hippocampal volume reduction in adults with post-traumatic stress disorder: a meta-analysis of structural MRI studies. Hippocampus 2005;15:798–807.
   PubMed Web of Science ®Google Scholar
• Filbey FM, McQueeny T, Kadamangudi S, Bice C, Ketcherside A. Combined effects of marijuana and nicotine on memory performance and hippocampal volume. Behav Brain Res 2015;293:46–53.
   PubMed Web of Science ®Google Scholar
• Ferreira-Vieira TH, Bastos CP, Pereira GS, Moreira FA, Massensini AR. A role for the endocannabinoid system in exercise-induced spatial memory enhancement in mice. Hippocampus 2014;24:79–88.
   PubMed Web of Science ®Google Scholar
• Hill MN, Titterness AK, Morrish AC, Carrier EJ, Lee TT, Gil-Mohapel J, Gorzalka BB, et al. Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus. Hippocampus 2010;20:513–523.
   PubMed Web of Science ®Google Scholar
• Biedermann SV, Fuss J, Steinle J, Auer MK, Dormann C, Falfán-Melgoza C, et al. The hippocampus and exercise: histological correlates of MR-detected volume changes. Brain Struct Funct 2016;221(3):1353–1363.
   PubMed Web of Science ®Google Scholar
• Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 2013;38:1557–1565.
   PubMed Web of Science ®Google Scholar
• Milman G, Bergamaschi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, Huestis MA. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence. Ther Drug Monit 2014;36:218–224.
   PubMed Web of Science ®Google Scholar
• Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA psychiatry 2014;71:281–291.
   PubMed Web of Science ®Google Scholar
• Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011;116:142–150.
   PubMed Web of Science ®Google Scholar
• Chauvet C, Nicolas C, Thiriet N, Lardeux MV, Duranti A, Solinas M. Chronic stimulation of the tone of endogenous anandamide reduces cue- and stress-induced relapse in rats. Int J Neuropsychopharmacol 2014;18: pyu025.
   PubMed Web of Science ®Google Scholar
• Justinova Z, Panlilio LV, Moreno-Sanz G, Redhi GH, Auber A, Secci ME, Mascia P, et al. Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse. Neuropsychopharmacology 2015;40:2185–2197.
   PubMed Web of Science ®Google Scholar
• Cippitelli A, Cannella N, Braconi S, Duranti A, Tontini A, Bilbao A, Defonseca FR, et al. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology 2008;198:449–460.
   PubMed Web of Science ®Google Scholar